The comparative immunogenicity of biologic therapy and its clinical relevance in psoriatic arthritis: a systematic review of the literature

References

• Sozzani S, Abbracchio MP, Annese V, et al. Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review. Autoimmunity. 2014;47:287–306.
   PubMed Web of Science ®Google Scholar
• Schellekens H, Jiskoot W. Immunogenicity of therapeutic proteins. In: Crommelin D., Sindelar R., Meibohm B. (eds). Pharmaceutical Biotechnology: Newyork, NY: Springer. 2013;133–141.
   Google Scholar
• Coates LC, Tillett W, Chandler D, et al. The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology. 2013;52:1754–1757.
   PubMed Web of Science ®Google Scholar
• Bandres Ciga S, Salvatierra J, Lopez-Sidro M, et al. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies. J Clin Rheumatol. 2015;21:115–119.
   PubMed Web of Science ®Google Scholar
• Mok CC, Tsai WC, Chen DY, et al. Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2016;16:201–211.
   PubMed Web of Science ®Google Scholar
• van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9:164–172.
   PubMed Web of Science ®Google Scholar
• Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72:1947–1955.
   PubMed Web of Science ®Google Scholar
• Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1739–1745.
   PubMed Web of Science ®Google Scholar
• Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72:165–178.
   PubMed Web of Science ®Google Scholar
• Rivera R, Herranz P, Vanaclocha F. Clinical significance of immunogenicity in biologic therapy. Actas Dermosifiliogr. 2014;105:1–4.
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–2272.
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150–1157.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis. 2007;66:498–505.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633–640.
   PubMed Web of Science ®Google Scholar
• Torii H, Nakagawa H. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci. 2010;59:40–49.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis. 2013;72:1777–1785.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014;73:1689–1694.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Keen M, Gunn G, et al. Immunogenicity and clinical relevance of ustekinumab in two phase 3 studies in patients with active psoriatic arthritis. Clin Pharmacol Drug Dev. 2013;2:32.
   Google Scholar
• McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17a monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase ii proof-of-concept trial. Ann Rheum Dis. 2014;73:349–356.
   PubMed Web of Science ®Google Scholar
• Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17a in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329–1339.
   PubMed Web of Science ®Google Scholar
• Goll GL, Olsen IC, Jorgensen KK, et al. Biosimilar inflixmiab (ct-p13) is not inferior to originator infliximab: results from a 52-week randomized switch trial in Norway. Arthritis Rheumatol. 2016;68(Suppl 10):19L.
   Google Scholar
• Torii H, Nakagawa H. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol. 2011;38:321–334.
   PubMed Web of Science ®Google Scholar
• van Kuijk AW, de Groot M, Stapel SO, et al. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis. 2010;69:624–625.
   PubMed Web of Science ®Google Scholar
• Cajigas D, Plasencia C, Pascual-Salcedo D, et al. The immunogenicity of biological therapies correlates with clinical efficacy in psoriatic arthritis (PsA) in long-term treatment with infliximab and adalimumab. Ann Rheum Dis. 2013;72(Suppl 3):A964–5.
   Google Scholar
• Garces S, Freitas J, Canas-Silva J, et al. The impact of immunogenicity on drug safety profile. Ann Rheum Dis. 2013;72(Suppl 3):A436.
   Google Scholar
• Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-tnfalpha biologics in rheumatic diseases. Clin Rheumatol. 2013;32:1429–1435.
   PubMed Web of Science ®Google Scholar
• Zisapel M, Marar-Balakirsi N, Padova H. Immunogenicity of TNF alpha blockers in patients with psoriatic arthritis. Arthritis Rheum. 2013;65:S1062.
   Google Scholar
• Zisapel M, Zisman D, Madar-Balakirski N, et al. Prevalence of TNF-alpha blocker immunogenicity in psoriatic arthritis. J Rheumatol. 2015;42:73–78.
   PubMed Web of Science ®Google Scholar
• Ataman S, Soltanalizade R, Tutkak H, et al. The relationship between immunogenicity, disease activity and autoantibody development in patients with rheumatic diseases treated with anti-TNF agents. Ann Rheum Dis. 2014;73(Suppl 2):FRI0272.
   Google Scholar
• Hoxha A, Calligaro A, Tonello M, et al. Clinical significance of anti-adalimumab antibodies in rheumatoid arthritis, ankylosing spondylitis and psorasic arthritis. Ann Rheum Dis. 2014;73:927.
   Web of Science ®Google Scholar
• Hoxha A, Calligaro A, Tonello M, et al. The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: a prospective multicentre study. Joint Bone Spine. 2016;83:167–171.
   PubMed Web of Science ®Google Scholar
• Rosas J, Llinares-Tello F, Senabre-Gallego JM, et al. Cut-off level of adalimumab and prevalence of antibodies anti-adalimumab in patients with ankylosing spondylitis: results from a local registry. Arthritis Rheum. 2014;66:S674.
   Web of Science ®Google Scholar
• Sanmarti R, Inciarte J, Estrada Alarcon P, et al. Immunogenicity of anti-TNF antagonists in patients with rheumatoid arthritits or polyarticular psoriatic arthritis in clinical remission or low disease activity: the inmunoremar study. Ann Rheum Dis. 2014;73(Suppl 2):FRI0265.
   Google Scholar
• Vogelzang E, Kneepkens E, Nurmohamed M, et al. A diminished clinical response at 28 and 52 weeks of adalimumab treatment in patients with psoriatic arthritis is associated with anti-drug antibodies. Ann Rheum Dis. 2014;73(Suppl 2):A735–6.
   PubMedGoogle Scholar
• Vogelzang EH, Kneepkens EL, Nurmohamed MT, et al. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Ann Rheum Dis. 2014;73:2178–2182.
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Triggianese P, Narcisi A, et al. Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response. J Int Med Res. 2016;44:48–52.
   PubMed Web of Science ®Google Scholar
• Rosas J, Llinares-Tello F, Senabre JM, et al. Evaluation of anti-TNF levels and anti-TNF antibodies in rheumatic diseases treated with infliximab and adalimumab: results from a local registry. Ann Rheum Dis. 2012;71(Suppl 3):664.
   Google Scholar
• Inciarte-Mundo J, Hernández MV, Cabrera S, et al. Immunogenicity induced by tumor necrosis factor antagonists in chronic inflammatory arthropathies: retrospective study in clinical practice conditions. Arthritis Rheum. 2013;65(Suppl 10):1444.
   Google Scholar
• Jani M, Chinoy H, Barton A, et al. Pharmacological monitoring of adalimumab and etanercept-treated psoriatic arthritis patients in predicting future treatment response. Arthritis Rheumatol. 2016;68(suppl 10):1695.
   Google Scholar
• Herold M, Boso L, Haueis T, et al. No need to detect anti-drug antibodies in patients treated with TNF inhibitors. Ann Rheum Dis. 2016;75(Suppl 2):691.
   Google Scholar
• Rosas J, Llinares-Tello F, Martín S, et al. Evaluation of serum level of golimumab and antibodies anti-golimumab in patients with rheumatic diseases: results from a local registry. Ann Rheum Dis. 2014;73(Suppl 2):AB0389.
   Google Scholar
• Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014;170:261–273.
   PubMed Web of Science ®Google Scholar
• Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2014;53:213–222.
   PubMed Web of Science ®Google Scholar
• Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med. 2013;173:1416–1428.
   PubMed Web of Science ®Google Scholar
• Behrens F, Canete JD, Olivieri I, et al. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. Rheumatology (Oxford). 2015;54:915–926.
   PubMed Web of Science ®Google Scholar
• Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov. 2007;6:75–92.
   PubMed Web of Science ®Google Scholar
• Ordas I, Mould DR, Feagan BG, et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91:635–646.
   PubMed Web of Science ®Google Scholar
• Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs. 2010;24:23–39.
   PubMed Web of Science ®Google Scholar
• Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11:81–88.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Talotta R, Salaffi F, et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev. 2013;12:703–708.
   PubMed Web of Science ®Google Scholar
• Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31:299–316.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(1320–9):e3.
   Google Scholar